Relmada Therapeutics, Inc. RLMD Net Operating Loss Carryforwards
Net Operating Loss Carryforwards at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLossCarryforwards.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s net operating loss carryforwards.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s net operating loss carryforwards?
- Relmada Therapeutics, Inc. (RLMD) reported net operating loss carryforwards of $4.77M in Q4 2025.
- How has Relmada Therapeutics, Inc.'s net operating loss carryforwards changed year-over-year?
- Relmada Therapeutics, Inc.'s net operating loss carryforwards decreased by 91.0% year-over-year, from $53.03M to $4.77M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s net operating loss carryforwards?
- Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s net operating loss carryforwards has grown at a -12.6% compound annual growth rate (CAGR), from $9.36M to $4.77M.
- What does net operating loss carryforwards mean?
- These are tax assets representing losses that can be used to reduce taxable income in future periods. They provide a potential future tax shield, improving cash flow by lowering future tax payments. Investors monitor these to estimate the duration and magnitude of potential tax savings.